Filing Flows › Pure Bioscience (PURE) › Q3 FY26
Pure Bioscience (PURE) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Jun 15, 2026
Pure Bioscience (PURE) reported revenue of $506K for the third quarter fiscal 2026 (Q3 FY26), +3% from a year earlier and +14% from the quarter before. Operating margin was -102.4%, net loss $624K (123.3% of revenue).
Pure Bioscience, Q3 FY26: revenue $506K (+4% year over year), operating margin -102.4%, net loss $624K, operating cash flow −$468K. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $506K | +14% | +3% |
| Operating profit | −$518K | — | — |
| Net earnings | −$624K | — | — |
| Operating cash flow | −$468K | — | — |
What changed
Revenue was $506K in Q3 FY26, up 3% year over year and up 14% from the previous quarter. SILVERION was the largest line at 82% of revenue. SILVERION added $393K year over year (up 1871%), 2312% of the total change. PURE Hard Surface declined 80%.
Gross margin was 53.2%, down 4.7 points from Q3 FY25. Operating costs exceeded revenue by $518K, an operating margin of -102.4%. Operating expenses fell 9% while revenue rose 3%. The quarter ended with a net loss of $624K, narrower than the previous quarter's $785K loss.
Operating cash flow was −$468K. Non-cash charges added back $55K of share-based compensation. Working capital and other items added $101K.
Questions
What was Pure Bioscience's revenue in the third quarter fiscal 2026?
Pure Bioscience (PURE) reported revenue of $506K for the third quarter fiscal 2026 (Q3 FY26), +3% from a year earlier and +14% from the quarter before.
Was Pure Bioscience profitable in the third quarter fiscal 2026?
Operating loss was $518K (-102.4% of revenue) and net loss $624K.
Source: Pure Bioscience 10-Q on SEC EDGAR.